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Patient follow up screening evaluations. Examples
with regard to congenital hip dislocation and
congenital heart disease
R E Juttmann, J Hess, G J van Oortmarssen, P J van der Maas
Abstract
Objective—To discuss the merits of the
patient follow up study design for the
evaluation of some specific mass screen-
ing programmes.
Design—Theoretical evaluation illus-
trated by two examples.
Setting—Department of Public Health
Erasmus University Rotterdam.
Main results—The gold standard for
evaluation of favourable eVects of screen-
ing is the randomised controlled trial
(RCT). Application of an RCT, however, is
often not feasible, in which cases observa-
tional studies will have to be relied on. The
case-control study design is generally
considered to be second best. In some
situations, however, a patient follow up
study design may be applicable and may
have some major advantages. The use of
the patient follow up design for screening
evaluation will often be very problematic
or even unacceptable, particularly as far
as screening for cancer is concerned. The
most important objections are resulting
from lead time bias, length bias, selection
bias and over-treatment bias. For the
evaluation of screening for congenital
heart disease and congenital hip disloca-
tion in Dutch child health care, however,
these objections may relatively simply be
overcome. Lead time bias will be of little
importance, as the ages of onset of these
disorders are fixed, namely at birth, and
their ultimate outcomes may be expected
within relatively short time. Length bias
may largely be avoided by correction for
severity of the disorder, which can be
adequately assessed by modern diagnostic
procedures. Selection bias is generally
hard to rule out, but in these cases it prob-
ably plays a minor part. Over-treatment
can be avoided by the policy of “watchful
waiting”, which in these disorders can be
applied with little risk for fatal outcomes.
In principle bias might be avoided more
successfully in a case-control screening
evaluation than in a patient follow up
study. However, the patient follow up
study is for both screening programmes
discussed here the more feasible design
and can provide more supplementary
information. The results of two example
studies suggest that both screenings prob-
ably yield considerable benefits
Conclusion—Under a number of specific
conditions a patient follow up study is an
eYcient alternative to more customary
designs for screening evaluation.
(J Epidemiol Community Health 2001;55:126–131)
Although the basic concept of screening is
deceptively simple, there is a general consensus
that assessing the favourable eVects of any
screening programme is fraught with pitfalls
and requires a very strict methodology.1 From a
theoretical point of view the most appropriate
design for such studies is the randomised con-
trolled trial (RCT), which in principle is the
only option to avoid virtually all types of
confounding.2 Unfortunately, many forms of
screening already have an established place in
health care without ever having been subjected
to a randomised trial. Examples are to be found
in occupational health, cervical cancer screen-
ing, the periodic examinations during preg-
nancy and child health care. If a screening pro-
gramme is already performed on a large scale
in a population, it is almost impossible to
organise an RCT for the evaluation of such a
programme. Definite faith in the benefits of
screening among many professionals and the
public, will, although based on merely circum-
stantial evidence, lead to strong resistance, if
the screening is withheld from persons who
normally would have had the opportunity to
participate. When an RCT for assessing
favourable eVects of an already existing screen-
ing programme is not feasible, one has to rely
on less decisive observational studies, meticu-
lously considering possible sources of con-
founding. The most common observational
designs for this purpose are the population fol-
low up study and the case-control study. This
paper, however, is mainly concerned with the
merits and shortcomings of the patient follow
up study, which may be considered as an alter-
native for the case-control study.
For many conditions, especially for cancer,
the use of the patient follow up study design for
assessing favourable eVects of screening is very
problematic, or even unacceptable. However,
for the evaluation of screening for some disor-
ders with specific characteristics, this design
may, under a number of strict conditions, be
useful. This may particularly be the case for
evaluation of screening for some congenital
disorders within the framework of child health
care.
After a short description of the patient follow
up study design for assessing favourable eVects
of screening, we will first discuss the most
important objections against this kind of study,
notably as far as cancer screening is concerned.
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Next we will demonstrate why these objections
may be less problematic, or may be relatively
easily be remedied, in assessing the eVects of
screening for certain conditions in child health
care, in particular congenital heart malforma-
tions and congenital hip dislocation. Finally, we
will review two examples of screening evalua-
tions, in which for these conditions the patient
follow up study design was actually applied.
The design
In a screening evaluation according to the
patient follow up study design, a representative
group of patients is followed up from diagnosis
until the outcome of treatment can be
established. Retrospectively the exposure to
screening will be established. If the odds for
reaching an adverse outcome are more favour-
able for well screened patients (the screening
group) than for patients not or scarcely
exposed to screening (the non-screening
group), the screening is considered to be eVec-
tive.
Objections against patient follow up
studies in cancer screening
There are four evident objections against
patient follow up evaluations of cancer screen-
ing:
LEAD TIME BIAS
Considering the nature of most cancers, the
follow up time after diagnosis, in which the
outcome of the treatment is supposed to be
established in patient follow up screening
evaluations, is not fixed. Because for most can-
cers the adverse outcome to be prevented is
death, the usual outcome measure is whether
or not patients will survive a fixed period after
diagnosis of for example five years. As the age
of onset of cancer in relation to the age of
screening may vary considerably, the screening
group may contain a large proportion of
patients with disorders in an early stage. Many
of these patients will, regardless of being
treated or not, probably not die within five
years, but may despite receiving treatment still
die from cancer after five years. In the
non-screening group such patients will be
virtually absent. This will lead to an overesti-
mation of the proportion of patients with
favourable outcomes in the screening group
and consequently to overestimation of the
potential favourable eVects of screening.
LENGTH BIAS
Patients with rapidly progressing cancers are
more likely to reach an adverse outcome than
patients with slowly progressing diseases, while
they have also less chance of being screened
during the short preclinical detectable phase.
In a comparison of screen detected with
non-screen detected patients this will lead to an
overrepresentation of such patients in the non-
screen detected group and consequently to
overestimation of the favourable eVects of
screening. This kind of contamination is called
“length bias”. In a patient follow up study in
which exposure to screening rather than detec-
tion by screening is the subject of the compari-
son, length bias is not necessarily a problem.
However, when rapid progression is somehow
connected with a decreased participation in the
screening programme, overestimation of fa-
vourable eVects of screening as a result of
diVerences in natural course will also occur in
this design.
SELECTION BIAS
People who have a better chance of being diag-
nosed in time and treated with favourable out-
comes without screening anyway, may also be
the better screened. For example, people who
are watchful as far as their health is concerned
and who are assertive in acquiring treatment,
probably scrupulously attend the screening
programme. This will also lead to an overesti-
mation of the eVectiveness of screening.
OVER-TREATMENT
Another problem in the patient follow up study
design is the potential presence among those
who were apparently treated successfully, of
persons who were wrongly indicated as a
patient by screening in the first place. This is a
general problem in cancer screening: the natu-
ral course of anomalies found by cancer
screening may vary considerably. Conditions
may be regressive and resolve spontaneously or
may be slowly progressive and never become a
real threat. Generally speaking it would be a
sensible policy to postpone treatment of screen
detected disorders until the disease has almost
progressed up to a stage in which a favourable
outcome can no longer be expected. This may
be feasible for disorders of which the prognosis
is relatively easy to establish, yet in many
cancers the natural course is quite unpredict-
able and a policy in which treatment is
postponed may easily lead to fatal outcomes. In
these cases therapeutic interventions will there-
fore be applied without delay. Hence over-
treatment must be considered as an inevitable
consequence of screening for many cancers, of
which cervical cancer and prostate cancer are
obvious examples.3 4 In the light of the possible
benefits of screening such a disadvantage may
be acceptable. However, in a patient follow up
cancer screening evaluation, this may also lead
to overestimation of the favourable eVects of
screening as in such a study favourable
outcomes in over-treated screening partici-
pants will contribute to the observed positive
eVect of the screening.
Status of these objections in screening for
congenital heart malformations and
congenital hip dislocation
LEAD TIME
The most important diVerences of these
conditions compared with cancer are that their
ages of onset are fixed, namely at birth, and that
their ultimate outcomes may be expected
within a relatively short time.
Both congenital hip dislocation and congeni-
tal heart malformations are in principle present
at birth. A persistent untreated dislocation will
almost inevitably reach the adverse outcome—
that is, limping—shortly after the age of 1 year.
In most untreated clinically significant
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congenital heart malformations the adverse
outcomes—that is, heamodynamic complica-
tions such as heart failure and hypoxemia—will
occur even before the age of 1 year. As a result
lead time bias will not occur in evaluating the
screening programmes for these congenital con-
ditions with a patient follow up design, in
contrast with the situation in cancer screening.
LENGTH BIAS
In patient follow up studies for congenital heart
malformations length bias may not be ruled
out. Screening examinations for this condition
are scheduled relatively close together in the
first months of life. Patients with severe
disorders may deteriorate rapidly and conse-
quently fail to attend the screening examina-
tion. Subsequently after diagnosis they may be
included in the non-screening arm of a patient
follow up study and may be considered to be
diagnosed after the adverse outcome was
reached. Such a sequence of events is less likely
in patients with moderate disorders, so such
patients may be over-represented in the
screening group and the non-adverse outcome
group, which will result in a overestimation of
the favourable eVects of screening. This might
be neutralised by correcting the analysis for
severity of the disorder. Reliable assessment of
severity—that is, the tendency to a rapid
deterioration—is obviously a requirement for
such a solution. In contrast with cancer, which
often is a condition developing, as it were, in
disguise, in congenital heart disease, current
diagnostic procedures make it possible to visu-
alise the malformation completely and thus
establish its severity reliably.5
SELECTION BIAS
As in all observational designs stringently
ruling out selection bias is one of the most
arduous problems in patient follow up screen-
ing evaluations. Nevertheless, in an observa-
tional evaluation of child health care screening,
selection bias may play a somewhat less impor-
tant part than in similar evaluations of cancer
screening. Selection bias is related to the extent
to which, and the reason why, people comply
with the invitation for the screening. However,
in the screening programmes under discussion,
exposure to screening generally does not
depend on the compliance of the parents
(which is usually very high), but above all on
whether or not screening is well performed by
the child health centre physician. Variation in
this performance will not automatically lead to
selection bias.
OVER-TREATMENT
As clarified above, postponing treatment until
the disorder almost reaches a stage in which
spontaneous regression is judged to be impos-
sible is the obvious strategy to prevent
over-treatment. This policy of “watchful wait-
ing” enables researchers to exclude screening
participants wrongly picked out as “patients”
from a patient follow up screening evaluation.
In contrast with many forms of cancer, in
which predicting the natural course is very
hazardous, this is relatively straightforward for
the congenital conditions under discussion.
While many cancers develop on a cellular level,
these conditions are generally relatively large
anatomical malformations. Congenital heart
and hip disorders may nowadays also be com-
pletely visualised, with the help of for example
ultrasound technology.6 Consequently the
natural course of both conditions can be moni-
tored adequately and interventions can be
postponed until deterioration can be accurately
foreseen.
Examples of patient follow up screening
evaluations in child health care
During the preparation of our child health care
evaluation programme we perceived that con-
genital heart disease and congenital dislocation
of the hip may have the specific characteristics
that allow applying a patient follow up screen-
ing evaluation. Thus we decided to conduct
two studies with such a design on these
diseases.
CONGENITAL HEART DISEASE
About 0.8% of all children are born with con-
genital heart disease. Large anatomical anoma-
lies, in which spontaneous recovery is incon-
ceivable, are treated immediately after
diagnosis by medication, catheterisation or
surgery. In all other cases, the natural course of
the disorders is surveyed until spontaneous
regression occurs—that is, the disorder disap-
pears or proves to be haemodynamically insig-
nificant, or until the adverse outcome of the
disease (heart failure or hypoxemia) is judged
to be inevitable unless treatment is started.7
After the neonatal check up by the doctor or
midwife who assisted birth, which is not stand-
ardised in the Netherlands, the cardiovascular
system of children in the Netherlands is
screened during recurrent physical examin-
ations in the child health care programme.
KEY POINTS
x The gold standard for evaluation of
favourable eVects of screening is the ran-
domised controlled trial (RCT).
x Application of an RCT is often not feasi-
ble, in which cases observational designs
will have to be relied on of which the
case-control study design is generally
considered to be second best option.
x The most important objections against
patient follow up screening evaluations
are related to lead time bias, length bias,
selection bias and over-treatment bias.
For the evaluation of screening for
congenital heart and hip disorders, how-
ever, these objections may relatively
simply be overcome.
x Although in principle in a case-control
screening evaluation selection bias might
be avoided more successfully than in a
patient follow up study, for several
screening programmes in child health
care the latter is the more feasible design
and can provide more supplementary
information.
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From 1994 until 1996 in the Sophia
Children Hospital in Rotterdam a patient
follow up study was carried out, comprising 82
children with congenital heart disease.8 Chil-
dren were classified in the adverse outcome
category (diagnosed “too late”) if heart failure
or hypoxemia had occurred before diagnosis.
Children who could be treated before the onset
of heart failure or hypoxemia was judged to be
inevitable were classified in the non-adverse
outcome category (diagnosed “in time”). Chil-
dren were classified as “adequately screened” if
they had at least been exposed to all scheduled
screening tests in the child health care
programme until being diagnosed and if all
these screening tests had been performed
adequately—that is, in accordance with the
guidelines of the child health care authorities.
All others were classified as “inadequately
screened”. The number of children in each of
the four categories and the odds ratio for
reaching the adverse outcome depending on
whether or not being adequately screened are
presented in table1. As the disorders were also
classified as moderate, severe or very severe by
paediatric cardiologists, analysis could be
corrected for severity.
The results of this study show that systematic
screening in child health care can prevent
episodes of heart failure and hypoxemia in chil-
dren with congenital heart disease, although
after correction for severity the confidence
intervals for the odds ratio just includes 1.
CONGENITAL HIP DISLOCATION
About 1% of all children are born with a hip
dislocation or a dislocatable hip. In the absence
of (early) intervention this disorder will de-
velop into a permanent anomaly, which finally
results in limping, in only 0.08–0.16 % of all
children.9 Neonatal screening by the Barlow
and Ortolani methods is applied, for instance
in the United Kingdom and Scandinavia.10
Splinting for four to six weeks starting as soon
as possible after birth is often considered an
eVective and little taxing intervention. How-
ever, as in 90% of the cases the disorder will be
regressive, the number of children apparently
treated successfully, but actually wrongly
picked out as a patient by screening will be
substantial. Therefore at first sight this pro-
gramme seems to be a poor candidate for
evaluation with a patient follow up study
design.
Some authors, however, advise to postpone
intervention until approximately the fifth
month.9 If the disorder still exists at that age it
can safely be considered as an anomaly that will
not recover without treatment. Splinting at that
age will generally still be successful, though
more taxing than in the very young children.
Surgery however will be avoided, as will
over-treatment.
As in Great Britain screening and interven-
tion are applied on a large scale soon after
birth, evaluation by an RCT is problematic.10
As in Great Britain the mere existence of con-
genital dislocation after the age of 1 month is
considered the adverse outcome to be avoided,
in that country a patient follow up study, as
presented in this paper will be of no use. If, for
instance, the need for surgery would be
considered as the adverse outcome to be
avoided, such study would become a possi-
bility.
In the Netherlands there is no neonatal
screening programme for congenital hip dislo-
cation. Instead, children are screened much
later during periodic physical examinations in
the child health care programme, which
include assessment of the abduction range of
the hips and the length of the legs.11 In the
Sophia Childrens Hospital in Rotterdam,
treatment policy is expectant: splinting is post-
poned until spontaneous recovery has become
very unlikely. Under these circumstances the
need for surgery is a useful definition of the
adverse outcome, and the patient follow up
design a possible option for screening evalua-
tion.
In 1992 a study was carried out in the Sophia
Children Hospital, comprising 60 children
with a congenital hip dislocation.12 All these
children had progressive disease: pathological
changes progressed up to a stage in which
spontaneous recovery of the dislocation was
judged to be impossible, before treatment was
applied. Children were classified in the adverse
outcome category if surgery was needed and in
the no adverse outcome category if they were
successfully treated by non-invasive methods.
Children were classified as “adequately
screened” if until the definite diagnosis they
had been at least exposed to all scheduled
screening tests in the child health care
programme and if all these screening tests were
performed adequately—that is, in accordance
with the child health care professional guide-
lines. All other children were classified as
“inadequately screened”. The results and the
estimated odds ratio are presented in table 2.
The results of this study support the idea
that systematic screening in child health care
can prevent the necessity of surgical interven-
tion for congenital hip dislocation.
Table 1 2 × 2 table for analysis of a pilot patient follow up
study for the evaluation of child health care screening for
congenital heart malformations
“Too late” “In time” Total
Adequately screened 2 10 12
Inadequately screened 37 33 70
Total 39 43 82
Odds ratio for being “too late” depending on whether or not
adequately screened:
2:10/37:33 = 0.18 (95% CI: 0.04, 0.87)
= 0.20 (95% CI: 0.04, 1.05) corrected for severity
Table 2 2 × 2 table for analysis of a pilot patient follow up
study for the evaluation of child health care screening for
congenital hip dislocation
Necessity
for surgery
Conservative
intervention
possible Total
Adequately screened 6 13 19
Inadequately screened 26 15 41
Total 32 28 60
Odds ratio for necessity for surgery depending on whether or
not adequately screened.
6:13/26:15 = 0.27 (CI: 0.08, 0.85)
Patient follow up screening evaluations 129
www.jech.com
 on 28 November 2006 jech.bmj.comDownloaded from 
Discussion
The first question to be answered here is
whether it is worthwhile to apply second best
evaluation designs in situations where an RCT
is not feasible because of established practice
and circumstantial evidence for at least some
eVectiveness of the intervention. In our opinion
the answer depends on the quality of the
circumstantial evidence and the chance of fur-
ther improving the intervention. As review of
the available literature reveals large gaps in our
knowledge of the eVectiveness of screening
protocols in child health care,13 14 we believe
that observational studies for evaluation of the
benefits of these screenings are justified.
We believe that for at least congenital hip
dislocation and congenital heart disease a
partly retrospective partly prospective patient
follow up study can be an eYcient alternative
for more customary designs for screening
evaluation like the population follow up study
and the case-control study.
In terms of eYciency a patient follow up
study oVers the advantage of the availability of
a study group directly from the patient popula-
tion of for instance an academic hospital
providing specialised medical care to a large
area. Thus the laborious collection of data in
the general population, necessary in a popula-
tion follow up study, can be avoided.
Case-control studies provide another rela-
tively eYcient alternative for assessing favour-
able eVects of screening. In such a study the
case group consists of patients who have
reached the adverse outcome of the condition.
The exposure to screening in this group is ret-
rospectively compared with that in a control
group. To minimise bias, this control group
should be sampled directly from the total
population that generated the cases: the source
population.2 15 In practice complying with this
condition may not be easy. To form a sample
from the source population, reliably presenting
the average exposure to screening in that
population may, especially if data concerning
this population are not easily available, be more
problematic than gathering complete data of
relevant patients from a circumscribed area in a
well defined time window, as required in a
patient follow up study.
In screening evaluations by case-control
studies one has to deal with the so called
“healthy-screenee-bias”. Once a disease is
diagnosed the patient is thereafter no longer
screened, while “healthy” non-patients are
screened again and again. As the control group
(almost) exclusively consists of “healthy” non-
patients this phenomenon will, if the total
number of applied screening tests per study
participant is used to quantify the screening
history, lead to an overestimation of the
eVectiveness of screening. To avoid this bias
controls and cases are matched for age, and
assessment of exposure to screening in a
control is exclusively aimed at the period up to
the age that the matched case was diagnosed.
Matching for other variables may be hazard-
ous, as it may introduce new sources of
confounding. In Dutch child health care, for
instance, diVerences in exposure to screening
within the population are probably strongly
connected with diVerences in screening per-
formance in child health centres.Matching, for
example, for living area may easily lead to
matching for child health centre as well. Should
there be a real eVect of screening, this would
lead to an underestimation of the average
exposure in the source population, and conse-
quently to an underestimation of the favour-
able eVect of screening.
An advantage of patient follow up studies is
that healthy-screenee-bias is ruled out, al-
though a similar problem remains. The total
number of applied screening tests per indi-
vidual cannot be used to establish the screening
history in patient follow up studies in child
health care either. Cases diagnosed early in life
may have a better chance of being successfully
treated, but will be exposed to fewer screening
tests than those who are diagnosed later.
Therefore using the total number of applied
screening tests as a measure for screening
history would lead to underestimation of the
eVectiveness of screening. To avoid this bias in
establishing the screening history the pro-
portion of scheduled screening examinations
that have actually been carried out until the age
of the definite diagnosis should be used.
Patient follow up studies (as well as case-
control studies) aim exclusively at estimating
the favourable eVects of screening and not at
weighing advantages and disadvantages (for
example, arising from false positive and false
negative tests). This requires additional data
collection.
A remarkable characteristic of case-control
screening evaluations is the fact that although
such studies are aimed at assessing benefits of a
screening not a single person who actually
benefits from screening may be included in the
study. The case group consists of people with
adverse outcomes of the condition, the control
group virtually always consists of people who
do not have the condition at all. As a result, in
case-control screening evaluations, only the
prevention process as a whole starting from
exposure to screening can be evaluated. The
contribution of separate factors, such as the
influence of delay between a positive screening
test and adequate diagnosis and intervention,
which may be of crucial importance for the
eVectiveness of the prevention programme,
cannot be evaluated. In a patient follow up
study, however, this is very well possible.
If in a case-control screening evaluation a
truly representative sample can be taken from
the source population, selection bias will prob-
ably be avoided more successfully than in a
patient follow up study in which correction for
such contamination is not straightforward. The
patient follow up study, however, is for both
screening programmes discussed here the more
feasible design and will provide more supple-
mentary information. The results of the trials
presented in this study indicate that both
screenings might yield considerable benefits.
The odds ratios presented are very low. One is
tempted to conclude that, even if selection bias
would play a part, there must be also a real
eVect of screening.
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The final conclusion is that under a number
of specific conditions a patient follow up study
is an eYcient alternative to more customary
designs for screening evaluation.
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